



Patent  
Attorney Docket No. 032,290-007  
(formerly ARTM 1000-6US)

#C07e  
#19  
M.F.D.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Fulton, et al..

Patent No: 6,730,042 B2

Issued: May 4, 2004

Serial No.: 10/027,157

Filed: December 20, 2001

Title: BIOPSY LOCALIZATION METHOD  
AND DEVICE

**Certificate**  
**JUN 14 2004**  
**of Correction**

**TRANSMITTAL OF REQUEST FOR CERTIFICATE OF CORRECTION**

Mail Stop: Certificate of Correction Branch  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed for filing, please find the following:

1. Request for Certificate of Correction of Patent for Office Mistake (37 CFR 1.322(a)) and Applicant's Mistake (37 CFR 1.323);
2. Certificate of Correction (Form PTO/SB/44); and
3. COPY of Amendment and Response dated December 1, 2003 and Response dated February 9, 2004.

06/09/2004 AWONDAF2 00000210 502862 6730042  
01 FC:1811 100.00 DA

**CERTIFICATE OF MAILING (37 C.F.R. §1.8a)**

I hereby certify that I have reasonable basis to expect and believe that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 3, 2004  
Date of Deposit  
IR1:1055442.1

*Cynthia B. Pacheco*  
Cynthia B. Pacheco

14 JUN 2004

4. The Commissioner is hereby authorized to charge Deposit Account No. 50-2862 in the amount of \$100.00. The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayments to Deposit Account 50-2862.

Please send the Certificate to:

John Kappos, Esq.  
O'Melveny & Myers LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618

Respectfully submitted,  
O'MELVENY & MYERS LLP

Dated: June 3, 2004

By: Diane K. Wong  
Diane K. Wong  
Reg. No. 54,550

DKW/kmg  
Enclosures

114 Pacifica, Suite 100  
Irvine, CA 92618  
(949) 737-2900



Patent  
Attorney Docket No. 032,290-007  
(formerly ARTM 1000-6US)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Fulton, et al.

Patent No: 6,730,042 B2

Issued: May 4, 2004

Serial No.: 10/027,157

Filed: December 20, 2001

Title: BIOPSY LOCALIZATION METHOD  
AND DEVICE

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR  
OFFICE MISTAKE (37CFR 1.322(a)) AND APPLICANT'S MISTAKE (37 CFR 1.323)**

Mail Stop: Certificate of Correction Branch  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This request for Certificate of Correction is made pursuant to 35 U.S.C. §254 and 37 C.F.R. §1.322(a) (PTO mistake) and 35 U.S.C. §255 and 37 C.F.R. §1.323 (Applicant's mistake) to correct mistakes inadvertently made in the subject patent. Please correct the subject patent according to the attached Certificate of Correction. Attached in duplicate is Form-1050, with at least one copy being suitable for printing.


---

**CERTIFICATE OF MAILING (37 C.F.R. §1.8a)**

I hereby certify that I have reasonable basis to expect and believe that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 3, 2004

Date of Deposit  
IR1:1055440.1

  
Cynthia B. Pacheco

A Certificate of Correction is requested in the above-referenced Patent under 35 U.S.C. §254 and 37 C.F.R. §1.322(a) to correct mistakes made by the PTO in the printing of the claims.

Applicant requests that the subject patent be corrected as follows:

Column 10:

Claim 36

Change "claim" to -- claim 30 -- .

Claim 37

Change "claim" to -- claim 36 --.

Support for these corrections can be found on page 8, claims 67-68 in the Amendment and

Response filed on December 1, 2003 (Exhibit A) and in the Response dated February 9, 2004

(Exhibit B).

A Certificate of Correction is also requested under 35 U.S.C. §255 and 37 C.F.R. §1.323 (Applicant's mistake). Applicant requests that the subject patent be corrected as follows in order to correct grammatical mistakes.

Column 8

Claim 29

Delete "upon"

Column 10:

Claim 37

Delete "upon"

Please send the Certificate of Correction to John Kappos, O'Melveny & Myers LLP, 114 Pacifica, Suite 100, Irvine, California, 92618-3315, attorney of record for Assignees, Artemis Medical, Inc. The Commissioner is hereby authorized to charge Deposit Account No. **50-2862** in the amount of \$100.00 and any additional fees that may be required with this submission.

Respectfully submitted,

Dated: June 3, 2004

By: Diane K. Wong  
Diane K. Wong  
Reg. No. 54,550  
Attorneys for Applicant

O'MELVENY & MYERS LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618  
Phone: (949) 737-2900  
Fax: (949) 737-2300



Patent US 200C2  
Attorney Docket: 032,290-007  
(formerly ARTM 1000-6)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

FULTON et al.

Serial No.: 10/027,157

Filed: December 20, 2001

For: BIOPSY LOCALIZATION METHOD  
AND DEVICE

Group Art Unit: 3736

Examiner: B. Szmaj

**AMENDMENT AND RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action mailed June 30, 2003. Please amend the subject application as follows.

**Amendments to the claims** begin on page 2 of this paper.

**Remarks** begin on page 9 of this paper.

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, PO Box 1450 Alexandria, VA 22313-1450.

December 1, 2003  
Date of Deposit

*Cynthia B. Pacheco*  
Cynthia B. Pacheco

IR1:1049835.1

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of the Claims

1-3. (Canceled)

4. (Previously Amended) A soft target tissue localization device comprising:  
a bioabsorbable element locatable at a soft target tissue site of a patient;  
said bioabsorbable element being of a material which is palpably harder than the surrounding soft tissue at the soft target tissue site;  
said bioabsorbable element having a pre delivery state and a post delivery state:  
and the bioabsorbable element having, a longest dimension of at least about 0.5 cm when in the post delivery state.

5. (Previously Amended) The device according to claim 4 wherein the bioabsorbable element comprises a bioabsorbable filament.

6. (Previously Amended) The device according to claim 4 further comprising a marker element in contact with the bioabsorbable element.

7. (Original) The device according to claim 6 wherein the marker element is a radiopaque marker element.
8. (Original) The device according to claim 6 wherein the marker element is located generally centrally within the bioabsorbable element.
9. (Original) The device according to claim 6 wherein the marker element is a radiopaque marker element located generally centrally within the bioabsorbable element.
10. (Original) The device according to claim the 6 wherein the marker element is a permanent marker element.
11. (Original) The device according to claim the 6 wherein the marker element is a temporary marker element.
12. (Previously Amended) The device according to claim 4 wherein the bioabsorbable element has margins, said margins being roughened so to help prevent migration of the bioabsorbable element within soft tissue of a patient.
13. (Original) The device according to claim 12 wherein the bioabsorbable element has filaments extending from the margins.



14. (Original) The device according to claim 13 wherein the filaments are of same material as the bioabsorbable element.

15. (Previously Amended) The device according to claim 1 wherein the bioabsorbable element is remotely visualizable in its post delivery state by at least one of ultrasound and mammography.

16. (Previously Amended) The device according to claim 4 wherein the bioabsorbable element is softer in a post delivery state than in a pre delivery state.

17. (Original) The device according to claim 1 wherein the bioabsorbable element is of a different hardness in a post delivery state as in a pre-delivery state.

18-36. (Canceled)

37. (Original) A biopsy localization method comprising:  
taking a tissue sample from a biopsy site within a patient;  
positioning a bioabsorbable element at the biopsy site;  
testing the tissue sample; and  
if the testing indicates a need to do so relocating the biopsy site by finding the bioabsorbable element by following a bioabsorbable thread, the thread extending from the patient's skin to the bioabsorbable element.

38. (Original) The method according to claim 37 wherein the positioning step is carried out using said bioabsorbable element and a radiopaque marker.

39. (Original) The device according to claim the 38 wherein the radiopaque marker element is a permanent marker element.

40. (Original) The device according to claim the 38 wherein the radiopaque marker element is a temporary marker element.

41. (Original) The method according to claim 37 wherein the remotely visualizing step is carried out to by at least one of ultrasound, mammography and MRI.

42. (Previously Amended) The method according to claim 37 further comprising the step of selecting the bioabsorbable element so that after positioning at the target site, the bioabsorbable element has a hardness of at least about 1.5 times as hard as the surrounding tissue.

43. (Original) The method according to claim 37 further comprising the step of effectively preventing blood from contacting the bioabsorbable element until the bioabsorbable element is positioned at the target site, the effectively preventing step being carried out by using a hemostatic bioabsorbable element having a non hemostatic biodegradable outer layer.

44. (Original) The method according the claim 37 further comprising the step of placing a marker element within the bioabsorbable element.

45. (Original) The method according the claim 37 further comprising the step of placing a marker element at a generally central location within the bioabsorbable element.

46-54. (Canceled)

55. (New) A target tissue localization device comprising:  
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;  
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising polylactic acid and polyglycolic acid; and  
a radiopaque marker carried by the bioresorbable body.

56. (New) The target tissue localization device of claim 55, wherein the bioresorbable body is remotely visualizable by at least one of ultrasound and mammography.

57. (New) The target tissue localization device of claim 55, wherein the radiopaque marker is contained within the bioresorbable body.

58. (New) The target tissue localization device of claim 55, wherein the bioresorbable body comprises at least one bioresorbable body.

59. (New) The target tissue localization device of claim 55, wherein the bioresorbable body swells upon contact with body fluid.

60. (New) The target tissue localization device of claim 59, wherein the bioresorbable body swells upon to substantially fill the biopsy site.

61. (New) A method for marking a biopsy cavity comprising the steps of:  
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising polylactic acid and polyglycolic acid;  
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;  
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and  
testing the biopsy specimen.

62. (New) The method of claim 61, further comprising the step of relocating the biopsy site by detecting the radiopaque marker.

63. (New) The method of claim 61, wherein the bioresorbable body comprises at least one bioresorbable body.

64. (New) The method of claim 61, wherein the radiopaque marker is contained within the bioresorbable body.
65. (New) The method of claim 62, wherein the radiopaque marker is detected by mammography.
66. (New) The method of claim 62, wherein the radiopaque marker is detected by ultrasound.
67. (New) The method of claim 61, wherein the bioresorbable body swells upon contact with body fluid.
68. (New) The method of claim 67, wherein the bioresorbable body swells upon to substantially fill the biopsy site.

### REMARKS

Reconsideration of the rejections set forth in the Office Action mailed June 30, 2003, is respectfully requested. Claims 1-3, 18-36, and 46-54 have been canceled. Claims 55-68 have been newly added. Claims 4-17, 37-45, and 55-68 remain pending in this case. Support for these amendments can be found in the specification at, e.g., page 3, lines 1-3; page 6, lines 10-12; page 8, lines 4-9; and page 8, lines 20-25. Therefore, these amendments are made without introducing new matter.

#### Art Rejections

Claims 19, 23, 46, and 50 were rejected under 35 U.S.C. § 102(b) as being alleged anticipated by, or in the alternative, under 35 U.S.C. § 103(a) as being allegedly obvious over Haaga (U.S. Patent 5,487,392). Applicants have cancelled claims 19, 23, 46, and 50. Therefore, these rejections are now moot. Applicants also point out that Haaga does not teach or suggest a *“bioresorbable body comprising polylactic acid and polyglycolic acid”* or the inclusion of *“a radiopaque marker carried by the bioresorbable body,”* as required by the newly added claims.

#### Allowable Subject Matter

Applicants gratefully acknowledge the examiner's indication that claims 2-17 and 37-45 are allowable.

For all the foregoing reasons, Applicants assert the claims are in condition for allowance. Favorable action on the merits of the claims is therefore earnestly solicited. If any issues remain, please contact Applicants' undersigned representative at (949) 737-2900. The Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 50-2862.

Respectfully submitted,  
O'MELVENY & MYERS LLP

Dated: November 26, 2003

By: *Diane K. Wong*  
Diane K. Wong  
Reg. No. 54,550  
Attorneys for Applicants

JCK/DKW/cp

O'Melveny & Myers LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618-3315  
(949) 737-2900



Patent US 200C2  
Attorney Docket: 032,290-007  
(formerly ARTM 1000-6)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

FULTON et al.

Serial No.: 10/027,157

Filed: December 20, 2001

For: BIOPSY LOCALIZATION METHOD  
AND DEVICE

Group Art Unit: 3736

Examiner: B. Szmal

**RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action mailed February 2, 2004. Please amend the subject application as follows.

**Listing of the claims** begin on page 2 of this paper.

**Remarks** begin on page 9 of this paper.

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted to (703) 872-9306 on the date shown below addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

February 9, 2004

Date of Deposit

Cynthia B. Pacheco

Cynthia B. Pacheco

IRI:1052214.1

14 JUN 2004



**LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-3. (Canceled)

4. (Previously Presented) A soft target tissue localization device comprising:  
a bioabsorbable element locatable at a soft target tissue site of a patient;  
said bioabsorbable element being of a material which is palpably harder than the surrounding soft tissue at the soft target tissue site;  
said bioabsorbable element having a pre delivery state and a post delivery state:  
and the bioabsorbable element having, a longest dimension of at least about 0.5 cm when in the post delivery state.

5. (Previously Presented) The device according to claim 4 wherein the bioabsorbable element comprises a bioabsorbable filament.

6. (Previously Presented) The device according to claim 4 further comprising a marker element in contact with the bioabsorbable element.

7. (Original) The device according to claim 6 wherein the marker element is a radiopaque marker element.

8. (Original) The device according to claim 6 wherein the marker element is located generally centrally within the bioabsorbable element.

9. (Original) The device according to claim 6 wherein the marker element is a radiopaque marker element located generally centrally within the bioabsorbable element.

10. (Original) The device according to claim the 6 wherein the marker element is a permanent marker element.

11. (Original) The device according to claim the 6 wherein the marker element is a temporary marker element.

12. (Previously Presented) The device according to claim 4 wherein the bioabsorbable element has margins, said margins being roughened so to help prevent migration of the bioabsorbable element within soft tissue of a patient.

13. (Original) The device according to claim 12 wherein the bioabsorbable element has filaments extending from the margins.

14. (Original) The device according to claim 13 wherein the filaments are of same material as the bioabsorbable element.

15. (Previously Presented) The device according to claim 1 wherein the bioabsorbable element is remotely visualizable in its post delivery state by at least one of ultrasound and mammography.

16. (Previously Presented) The device according to claim 4 wherein the bioabsorbable element is softer in a post delivery state than in a pre delivery state.

17. (Original) The device according to claim 1 wherein the bioabsorbable element is of a different hardness in a post delivery state as in a pre-delivery state.

18-36. (Canceled)

37. (Original) A biopsy localization method comprising:  
taking a tissue sample from a biopsy site within a patient;  
positioning a bioabsorbable element at the biopsy site;  
testing the tissue sample; and  
if the testing indicates a need to do so relocating the biopsy site by finding the bioabsorbable element by following a bioabsorbable thread, the thread extending from the patient's skin to the bioabsorbable element.

38. (Original) The method according to claim 37 wherein the positioning step is carried out using said bioabsorbable element and a radiopaque marker.

39. (Original) The device according to claim the 38 wherein the radiopaque marker element is a permanent marker element.

40. (Original) The device according to claim the 38 wherein the radiopaque marker element is a temporary marker element.

41. (Original) The method according to claim 37 wherein the remotely visualizing step is carried out to by at least one of ultrasound, mammography and MRI.

42. (Previously Presented) The method according to claim 37 further comprising the step of selecting the bioabsorbable element so that after positioning at the target site, the bioabsorbable element has a hardness of at least about 1.5 times as hard as the surrounding tissue.

43. (Original) The method according to claim 37 further comprising the step of effectively preventing blood from contacting the bioabsorbable element until the bioabsorbable element is positioned at the target site, the effectively preventing step being carried out by using a hemostatic bioabsorbable element having a non hemostatic biodegradable outer layer.

44. (Original) The method according the claim 37 further comprising the step of placing a marker element within the bioabsorbable element.

45. (Original) The method according the claim 37 further comprising the step of placing a marker element at a generally central location within the bioabsorbable element.

46-54. (Canceled)

55. (Previously Presented) A target tissue localization device comprising:  
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;

a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising polylactic acid and polyglycolic acid; and  
a radiopaque marker carried by the bioresorbable body.

56. (Previously Presented) The target tissue localization device of claim 55, wherein the bioresorbable body is remotely visualizable by at least one of ultrasound and mammography.

57. (Previously Presented) The target tissue localization device of claim 55, wherein the radiopaque marker is contained within the bioresorbable body.

58. (Previously Presented) The target tissue localization device of claim 55, wherein the bioresorbable body comprises at least one bioresorbable body.

59. (Previously Presented) The target tissue localization device of claim 55, wherein the bioresorbable body swells upon contact with body fluid.

60. (Previously Presented) The target tissue localization device of claim 59, wherein the bioresorbable body swells upon to substantially fill the biopsy site.

61. (Previously Presented) A method for marking a biopsy cavity comprising the steps of:

providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising polylactic acid and polyglycolic acid;

removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;

inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and

testing the biopsy specimen.

62. (Previously Presented) The method of claim 61, further comprising the step of relocating the biopsy site by detecting the radiopaque marker.

63. (Previously Presented) The method of claim 61, wherein the bioresorbable body comprises at least one bioresorbable body.

64. (Previously Presented) The method of claim 61, wherein the radiopaque marker is contained within the bioresorbable body.

65. (Previously Presented) The method of claim 62, wherein the radiopaque marker is detected by mammography.

66. (Previously Presented) The method of claim 62, wherein the radiopaque marker is detected by ultrasound.

67. (Previously Presented) The method of claim 61, wherein the bioresorbable body swells upon contact with body fluid.

68. (Previously Presented) The method of claim 67, wherein the bioresorbable body swells upon to substantially fill the biopsy site.

**REMARKS**

Reconsideration of the rejections set forth in the Office Action mailed February 2, 2004, is respectfully requested. Claims 4-17, 37-45, and 55-68 remain pending in this case.

**Art Rejections**

Claims 55-60 were rejected under 35 U.S.C. § 102(e) as being alleged anticipated by Corbitt, Jr. et al. (USP 6,214,045). Claims 61-68 were rejected under 35 U.S.C. § 103(a) as being allegedly unpatentable over Foerster et al. (USP 6,228,055) in view of Corbitt, Jr. et al.

As discussed with Examiner Szmaj with respect to related U.S. Application Serial No. 09/900,801 (Our Ref: 032,290-006), applicants respectfully assert that Corbitt is not prior art to the claims pending herein. Specification support for all claims 55-68 can be found in U.S. Application Serial No. 60/090,243, filed June 22, 1998, the benefit of which is claimed in the present application. (See, e.g., page 7, lines 16-21, page 9, lines 11-15, and Figs. 3 and 4). Corbitt is not prior art because Corbitt did not describe, before June 22, 1998, a biopsy site marker comprising polylactic acid and polyglycolic acid or a method of using the same. Therefore, all claim rejections should be withdrawn.

**Allowable Subject Matter**

Applicants gratefully acknowledge the examiner's indication that claims 4-17 and 37-45 are allowable.



For all the foregoing reasons, Applicants assert the claims are in condition for allowance. Favorable action on the merits of the claims is therefore earnestly solicited. If any issues remain, please contact Applicants' undersigned representative at (949) 737-2900. The Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 50-2862.

Respectfully submitted,  
O'MELVENY & MYERS LLP

Dated: 2/7/04

By: John Kappos  
John Kappos  
Reg. No. 37,861  
Attorneys for Applicants

JCK/DKW/cp

O'Melveny & Myers LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618-3315  
(949) 737-2900

MODE = MEMORY TRANSMISSION

START=FEB-09 16:40

END=FEB-09 16:43

FILE NO. =354

STN NO.	COMM.	ABBR NO.	STATION NAME/TEL NO.	PAGES	DURATION
001	OK	a	917038729306	011/011	00:02:38

-O'MELVENY&MYERS LLP IRV04-

\*\*\*\*\* -

- \*\*\*\*\* -

949 737 2300- \*\*\*\*\*

## O'MELVENY & MYERS LLP

114 Pacifica, Suite 100  
Irvine, California 92618-3318  
TELEPHONE (949) 737-2900  
FACSIMILE (949) 737-2300

### FAX TRANSMITTAL

#### DATE & TIME:

Monday, February 09, 2004

#### TOTAL NUMBER OF PAGES:

11

#### TO:

Examiner B. Szmal  
U.S. Patent Office, Art Unit 3736

#### FAX NUMBER:

(703) 872-9306

#### TELEPHONE NUMBER:

#### FROM:

John Kappos, Reg. No. 37,861

#### RETURN FAX NUMBER:

(949) 737-2300

#### TELEPHONE NUMBER:

(949) 737-2900

### MESSAGE

Rc: Fulton et al.

U.S. Application Serial No. 10/027,157

Attorney Docket No. 032,290-007

(formerly docket ARTM 1000-6)

#### Document(s) attached:

1. Response - 10 pages

IF YOU DID NOT RECEIVE ALL PAGES, PLEASE CALL OUR FAX DEPARTMENT AT (949) 737-2981.

FILE NO.: 032, 290-007  
USER NO.: 13367  
RESPONSIBLE ATTY NAME: Diane K. Wong  
SPECIAL INSTRUCTIONS:

RETURN ORIGINAL TO: Cindy  
EXTENSION: 2974  
LOCATION: IR

This document is intended for the exclusive use of the addressee. It may contain privileged, confidential, or non-disclosable information. If you are not the addressee, or someone responsible for delivering this document to the addressee, you may not read, copy, or distribute it. If you have received this document by mistake, please call us promptly and securely dispose of it. Thank you.

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,730,042 B2

DATED : May 4, 2004

INVENTOR(S) : Fulton et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 8, line 40

Claim 29

Delete "upon".

Column 10, line 5

Claim 36

Change "claim" to -- claim 30 --.

col. 10, line 7

Claim 37

Change "claim" to -- claim 36 --.

Delete "upon".

MAILING ADDRESS OF SENDER:

John Kappos, Esq.  
O'MELVENY & MYERS LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618

PATENT NO. 6,730,042 B2

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

14 JUN 2004

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,730,042 B2

DATED : May 4, 2004

INVENTOR(S) : Fulton et al.

It is certified that error appears in the above-identified patent and that said Letters Patent  
is hereby corrected as shown below:

Column 8

Claim 29

Delete "upon".

Column 10

Claim 36

Change "claim" to -- claim 30 --.

Claim 37

Change "claim" to -- claim 36 --.

Delete "upon".

**MAILING ADDRESS OF SENDER:**

John Kappos, Esq.  
O'MELVENY & MYERS LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618

PATENT NO. 6,730,042 B2

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**14 JUN 2004**